THBS1 and cancer: The data presented in this study documents that when compared to using either 2DG or metformin alone as a potential anti-cancer treatment regimen, using the combination of the glycolytic inhibitor 2DG (5 mM) and metformin (2 mM) activates anti-angiogenic TSP1, inhibits the Akt/mTOR pathway and decreases the levels of cyclins, leading to inhibition of tubulogenesis, cell proliferation and migration in cancer endothelial cells (Figure 11).